Enristomig

DB29060InvestigationalProtein Based Therapies

INBRX-105 is a biologic drug. INBRX-105 is under investigation in clinical trial NCT03809624 (Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer).

Mechanism: Pharmacologically active on Programmed cell death 1 ligand 1 and Tumor necrosis factor receptor superfamily member 9
Curator reviewed
Code names: ES101 · INBRX-105

Resolves to

Compound

UNII3CX9U8V1CVCAS2539845-73-1

Targets

Q9NZQ7CD274Q07011TNFRSF9

What you can answer from here — as of June 17, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Enristomig, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account